Home » Research » Liv.52 HB (capsule)

Total no. of papers:6 - Clinical Papers:6, Experimental Papers:0
(Research papers based on Indications)

HD-03/ES in the management of Hepatitis B infection

  1. HD-03/ES: A Promising herbal drug for HBV antiviral therapy
    Premashis Kar1, Mohammed Asim1 Manash Pratim Sarma1 Pralhad. S. Patki,2
    1. Department of Medicine, Maulana Azad Medical College, New Delhi India.
    2. R&D Department, The Himalaya Drug Company, Bengaluru, India.
    Antiviral Research 84 (2009) 249–253

  2. Double-blind clinical trial of HD-03/ES versus placebo in the management of Chronic hepatitis B.
    Arun Kumar Mahto, Narayanan Unnikrishnan.1 Professor and Head, Dept. of Medicine, Rajendra Institute of Medical Sciences, Bariatu, Ranchi. Indian Journal of Clinical Practice 2010;21(5):247-251

  3. A Preliminary study on the safety and efficacy of HD-03/ES therapy in patients with chronic hepatitis B: A Prospective clinical study.
    A.K. Bhattacharya1 P.Patki2
    1. Department of Medicine, Government Medical College, Manjura Gate, Surat – 395001 Gujarat, India
    2. R&D Center, The Himalaya Drug Company, Makali, Bengaluru, India – 562123.,
    Journal of Herbal Medicine and Toxicology 2009; 3(2):137-141

  4. A Preliminary study on the safety and efficacy of HD-03/ES therapy in patients with chronic hepatitis B.
    Janardan Singh,1 Anupam Chakraborty,1 Sudhakaran C,1 Mukul Chandra Dhar2 Mitra SK2
    1. Department of Medicine, R.G. Kar Medical College, Kolkatta - 700 004, India
    2. R&D Center, The Himalaya Drug Company, Makali, Bengaluru, India – 562123.,
    Indian Journal of Clinical Practice 2006; 17(5): 39-43

  5. Reduction of HBsAg with decrease in viral load with herbal formulation, HD-03/ES: A case study.
    Kala Suhas Kulkarni,1 V.G. Bhagwat,1 U.V.Babu,1 S.K. Mitra,1 Mallikarjun N. Dixit, 1 Ashwin Kumar Meru, 1 Ekta Saxena, 1
    1. R&D Center, The Himalaya Drug Company, Makali, Bengaluru, India – 562123.
    Medicine Update (2002): (10), 7, 61-63

  6. Safety and efficacy of oral HD-03/ES given for six months in patients with chronic B virus infection.
    JS Rajkumar,1 MG Sekar1, SK Mitra2.
    1. Lifeline rigid Hospitals, Kilpauk, Chennai, Tamilnadu, 600010, India.
    2. R&D Center, The Himalaya Drug Company, Makali, Bengaluru, India – 562123.,
    World Journal of Gastroenterology 2007; 13(30): 4103-4107